Paul Ruljancich

Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trial

Patrick Bowden, Andrew See, Mark Frydenberg et al. · International Journal of Cancer · 2019 · 69 citations · Full text

Medicine, Oncology, Radiation Oncology +16

Extraprostatic Extension into Periprostatic Fat is a More Important Determinant of Prostate Cancer Recurrence than an Invasive Phenotype

Jada Kapoor, Benjamin Namdarian, John Pedersen et al. · The Journal of Urology · 2013 · 41 citations

Medicine, Oncology, Urology +17

Ductal variant prostate carcinoma is associated with a significantly shorter metastasis-free survival

Ken Chow, Justin Bedő, Dinesh Agarwal et al. · European Journal of Cancer · 2021 · 25 citations

Medicine, Oncology, Urology +11

Loss of <i>SNAI2</i> in Prostate Cancer Correlates With Clinical Response to Androgen Deprivation Therapy

Marek Cmero, Natalie J. Kurganovs, Ryan Stuchbery et al. · JCO Precision Oncology · 2021 · 15 citations · Full text

Medicine, Oncology, Urology +17

Five‐year outcomes of fractionated stereotactic body radiotherapy for oligometastatic prostate cancer from the <scp>TRANSFORM</scp> phase <scp>II</scp> trial

Andrew See, Paul Conway, Mark Frydenberg et al. · International Journal of Cancer · 2024 · 10 citations · Full text

Medicine, Radiation Oncology, Urology +15